This article highlights ten leading cell therapy companies, all of which have promising cell therapy products being evaluated in clinical trials. These 10 companies were chosen because they are market leaders with robust financial funding, novel technologies, and strong therapeutic pipelines. [Read more…]
Leading iPSC Mass Production Equipment Manufacturers
Induced pluripotent stem cells (iPSCs) represent a groundbreaking advancement in biotechnology. iPSCs are a type of pluripotent stem cell generated by reprogramming adult somatic cells to an embryonic-like state, allowing them to differentiate into virtually any cell type in the body. This innovative technology provides a powerful tool for regenerative medicine, disease modeling, and drug discovery by offering a patient-specific source of cells for research and therapeutic applications. [Read more…]
Do Stem Cell Treatments For Arthritis Work?
Can stem cell treatments for arthritis bring relief to those suffering from the disease? For all of human time, the swelling and aching of joints has been a common experience. As connective tissue breaks down over time, the result is stiffening, pain, and immobility. The three most common causes of arthritis include joint injuries, age-related wear and tear, and autoimmune disorders. While some people are luckier than others, few people seem to escape it entirely, which is why stem cell treatments for arthritis are intriguing to so many.
Today, the most common kinds of arthritis are osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PA).
Because BioInformant is a publisher of stem cell industry news, we understandably don’t offer stem cell treatments. However, our Founder is a stem cell patient, and as a company of analysts, we do our best to track this evolving industry. With this context, let’s dive into how stem cells are currently being utilized for the treatment of arthritis in novel and intriguing ways.
Factor Bioscience and Eterna Therapeutics Forge Partnership to Fast-Track iMSC Therapies for Cancer, Autoimmune, and Rare Diseases
Factor and Eterna Announce Exclusive Collaboration Agreement to Accelerate iPSC-derived MSC Therapies for Oncology, Autoimmune, and Rare Diseases
CAMBRIDGE, Mass., Oct. 17, 2024 — Factor Bioscience Inc. and Eterna Therapeutics Inc. announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, to develop and market certain induced pluripotent stem cell (iPSC)-based cell therapy products (in particular iPSC derived mesenchymal stem cells (iMSC) that are engineered to express certain cytokines) utilizing Factor’s cell reprogramming and gene-editing technologies, patents, and know-how. The agreement positions both companies with the potential to accelerate the development of advanced cell therapies in the oncology, rare disease, and autoimmune fields. [Read more…]
HELP Therapeutics announces FDA clearance of IND application for universal iPSC-derived HiCM-188 cell therapy for the treatment of end-stage heart failure
NANJING, China, Oct. 22, 2024 — HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for “Allogeneic Human iPSC-derived cardiomyocytes (HiCM-188) administered via intramyocardial injection during coronary artery bypass graft surgery.” [Read more…]
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- …
- 201
- Next Page »